Gamma-Valerolactone from bio-based levulinic acid as alternative to Gamma Butyrolactone by Dr Marijn Rijkers

InnoSyn, founded on May 1st, 2017, is an R&D services spin-off from DSM to specifically focus on chemical programs to go: levulinic acid, fatty acid building blocks, lignin valorization and BIOFOREVER, the EU BBI project.

10th International Conference on Bio-bases Marerials – Köln, Germany- May 10-11, 2017

InnoSyn, founded on May 1st, 2017, is an R&D services spin-off from DSM to specifically focus on chemical programs to go: levulinic acid, fatty acid building blocks, lignin valorization and BIOFOREVER, the EU BBI project.

Innosyn has developed with the University of Utrech a model based view of bio-based opportunities over the next 30 years, a combination of 60 chemicals and 252 existing and foreseeable processes. Example of what the model delivers is presented: adipic acid from bio-based levulinic acid resulting into a lower cost and lower carbon footprint partly bio-based adipic acid. The model also allows to select a preferred route out of 20 to produce levulinic acid from biomass, specifically wood.The same scheme applies to formic acid.

Innosyn has been working on developing a robust process from pinewood to levulinic and formic acids, and from levulinic acid to Gamma valeroactone

Innosyn is looking for partners to develop the levulinic acid tree industrially over the next 5-6 years.

Reason given for the spin-off: DSM continues to refocus on end-markets away from fundamental chemistry.

Advertisements